Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Stock Report

Market Cap: US$311.9m

Ironwood Pharmaceuticals Future Growth

Future criteria checks 2/6

Ironwood Pharmaceuticals's revenue and earnings are forecast to decline at 16.2% and 8.7% per annum respectively while EPS is expected to grow by 80.3% per annum.

Key information

-8.7%

Earnings growth rate

80.34%

EPS growth rate

Biotechs earnings growth23.7%
Revenue growth rate-16.2%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Oct 2025

Recent future growth updates

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too

Sep 10
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%

Jun 25
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 21
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
User avatar

LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects

LINZESS prescription growth indicates strong market acceptance, potentially increasing revenue as it gains market share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Earnings and Revenue Growth Forecasts

NasdaqGS:IRWD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027233241411412
12/31/2026264511411414
12/31/2025279281021024
6/30/2025309-83030N/A
3/31/2025318-327879N/A
12/31/20243511103104N/A
9/30/2024378-2124124N/A
6/30/20244019146147N/A
3/31/2024414-1,052148148N/A
12/31/2023443-1,002183183N/A
9/30/2023432-952227227N/A
6/30/2023427-917263263N/A
3/31/2023417182290290N/A
12/31/2022411175274274N/A
9/30/2022421168259259N/A
6/30/2022416173265265N/A
3/31/2022422527252252N/A
12/31/2021414528262262N/A
9/30/2021413530249249N/A
6/30/2021413509227227N/A
3/31/2021398143199199N/A
12/31/2020390106167169N/A
9/30/2020399111140145N/A
6/30/202042797118126N/A
3/31/2020440848897N/A
12/31/201942859411N/A
9/30/201943319-12-8N/A
6/30/2019367-153-69-69N/A
3/31/2019346-173N/A-82N/A
12/31/2018347-194N/A-71N/A
9/30/2018310-190N/A-89N/A
6/30/2018331-71N/A-94N/A
3/31/2018315-108N/A-104N/A
12/31/2017298-55N/A-101N/A
9/30/2017292-143N/A-110N/A
6/30/2017271-143N/A-80N/A
3/31/2017260-121N/A-53N/A
12/31/2016274-82N/A-26N/A
9/30/2016240-82N/A-26N/A
6/30/2016213-96N/A-52N/A
3/31/2016187-123N/A-71N/A
12/31/2015150-143N/A-107N/A
9/30/2015134-166N/A-110N/A
6/30/2015112-161N/A-123N/A
3/31/201591-173N/A-133N/A
12/31/201476-190N/A-156N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IRWD's earnings are forecast to decline over the next 3 years (-8.7% per year).

Earnings vs Market: IRWD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IRWD is expected to become profitable in the next 3 years.

Revenue vs Market: IRWD's revenue is expected to decline over the next 3 years (-16.2% per year).

High Growth Revenue: IRWD's revenue is forecast to decline over the next 3 years (-16.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IRWD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/03 09:26
End of Day Share Price 2025/11/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ironwood Pharmaceuticals, Inc. is covered by 29 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Patrick TrucchioBerenberg
David MarisBMO Capital Markets Equity Research